Health-Chem Corporation (HCLC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Health-Chem Corporation (HCLC) with AI Score 38/100 (Weak). Health-Chem Corporation focuses on transdermal drug delivery systems, specifically nitroglycerin patches for angina relief. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Health-Chem Corporation (HCLC) Healthcare & Pipeline Overview
Health-Chem Corporation researches, develops, manufactures, and markets transdermal drug delivery systems, primarily nitroglycerin patches for angina. Operating within the medical diagnostics and research sector, the company distributes its products through wholesalers, retail pharmacies, and other healthcare organizations, while also providing contract R&D services.
Investment Thesis
Health-Chem Corporation's focus on transdermal drug delivery systems presents a niche investment opportunity within the broader healthcare sector. The company's reliance on a single product, nitroglycerin patches, creates both potential and risk. Revenue stability depends heavily on the continued demand for this product and the absence of disruptive competitive alternatives. The company's negative profit margin of -27.9% indicates financial challenges requiring careful monitoring. Growth catalysts include successful contract R&D projects and potential expansion into new transdermal products. Investors should closely examine the company's ability to improve profitability and diversify its product line. The high beta of -26.02 suggests extreme volatility relative to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Gross margin of 9.8% suggests significant cost pressures in manufacturing and distribution.
- Profit margin of -27.9% highlights the company's struggle to achieve profitability, requiring close scrutiny of expense management.
- Beta of -26.02 indicates an inverse correlation with the market, suggesting the stock may move in the opposite direction of broader market trends.
Competitors & Peers
Strengths
- Specialized expertise in transdermal drug delivery.
- Established distribution network in the United States.
- Contract R&D services providing revenue diversification.
- Proprietary formulation of nitroglycerin patches.
Weaknesses
- High reliance on a single product (nitroglycerin patches).
- Negative profit margin indicating financial instability.
- Limited market capitalization restricts growth potential.
- Dependence on third-party manufacturers for some components.
Catalysts
- Upcoming: Potential new contract R&D agreements could boost revenue and profitability.
- Ongoing: Continued demand for transdermal nitroglycerin patches for angina relief.
- Upcoming: Successful development and launch of new transdermal products.
- Ongoing: Streamlining manufacturing processes to improve gross margins.
- Upcoming: Strategic partnerships with larger pharmaceutical companies.
Risks
- Ongoing: High reliance on a single product (nitroglycerin patches).
- Potential: Competition from generic nitroglycerin patch manufacturers.
- Potential: Regulatory changes impacting transdermal drug delivery systems.
- Ongoing: Negative profit margin indicating financial instability.
- Potential: Technological advancements in alternative drug delivery methods.
Growth Opportunities
- Expansion of Contract R&D Services: Health-Chem can leverage its expertise in transdermal technology to secure more contract research and development projects. The market for outsourced pharmaceutical R&D is projected to reach $57.2 billion by 2028, offering a substantial opportunity for growth. Success in this area would diversify revenue streams and reduce reliance on nitroglycerin patch sales. Timeline: Ongoing.
- Development of New Transdermal Products: The company can invest in developing new transdermal drug delivery systems for other therapeutic areas. The global transdermal drug delivery market is expected to reach $7.6 billion by 2027, presenting a significant growth opportunity. Focusing on niche applications with limited competition could provide a competitive advantage. Timeline: 3-5 years.
- Strategic Partnerships: Health-Chem can form strategic partnerships with larger pharmaceutical companies to co-develop and market new transdermal products. This would provide access to greater resources and distribution networks, accelerating market penetration. The pharmaceutical industry is increasingly reliant on partnerships for innovation and market access. Timeline: 1-2 years.
- Geographic Expansion: Expanding sales and distribution beyond the United States could unlock new markets for the company's nitroglycerin patches and other transdermal products. International markets offer significant growth potential, particularly in regions with aging populations and increasing prevalence of cardiovascular disease. Timeline: 2-3 years.
- Improved Manufacturing Efficiency: Investing in advanced manufacturing technologies can reduce production costs and improve gross margins. The pharmaceutical industry is constantly seeking ways to optimize manufacturing processes to enhance profitability. Implementing lean manufacturing principles and automation could significantly improve Health-Chem's financial performance. Timeline: Ongoing.
Opportunities
- Expansion of contract R&D services.
- Development of new transdermal drug delivery systems.
- Strategic partnerships with larger pharmaceutical companies.
- Geographic expansion into international markets.
Threats
- Competition from generic nitroglycerin patch manufacturers.
- Regulatory changes impacting transdermal drug delivery systems.
- Technological advancements in alternative drug delivery methods.
- Pricing pressures from managed care organizations and pharmacy benefit managers.
Competitive Advantages
- Specialized expertise in transdermal drug delivery systems.
- Established relationships with wholesalers and distributors.
- Proprietary formulation of transdermal nitroglycerin patches.
- Contract R&D capabilities providing diversified revenue stream.
About HCLC
Founded in 1970 and based in Emigsville, Pennsylvania, Health-Chem Corporation operates through its subsidiary, Transderm Laboratories Corporation, focusing on transdermal drug delivery systems. The company's primary product is the transdermal nitroglycerin patch, designed to provide relief from vascular and cardiovascular symptoms associated with angina pectoris (chest pain). These patches deliver medication through the skin, offering a convenient and controlled method of drug administration. In addition to its proprietary products, Health-Chem Corporation engages in research and development activities for third parties on a contract basis, leveraging its expertise in transdermal technology to support other companies' product development efforts. Health-Chem markets its products directly to wholesalers, distributors, retail pharmacy chains, mail-order pharmacies, and group purchasing organizations. It also reaches independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management companies indirectly. This multi-channel approach allows Health-Chem to reach a broad customer base across the United States. The company's focus on a niche market within the pharmaceutical industry allows it to concentrate its resources and expertise, but also makes it vulnerable to competition and regulatory changes within that specific area.
What They Do
- Researches and develops transdermal drug delivery systems.
- Manufactures transdermal nitroglycerin patches for angina relief.
- Markets its products directly to wholesalers and distributors.
- Sells indirectly to independent pharmacies and hospitals.
- Conducts research and development activities for third parties on a contract basis.
- Focuses on providing transdermal solutions for vascular and cardiovascular symptoms.
Business Model
- Develops and manufactures transdermal nitroglycerin patches.
- Sells products directly to wholesalers, distributors, and retail pharmacy chains.
- Generates revenue through contract research and development services.
- Indirect sales to independent pharmacies, hospitals, and managed care organizations.
Industry Context
Health-Chem Corporation operates within the medical diagnostics and research industry, a segment driven by innovation and regulatory oversight. The market for transdermal drug delivery systems is a niche within the broader pharmaceutical industry. Competition includes companies developing alternative drug delivery methods and generic manufacturers of nitroglycerin patches. Market trends favor patient-centric drug delivery systems, but regulatory hurdles and pricing pressures remain significant challenges. Health-Chem's success depends on its ability to maintain market share in its niche and adapt to evolving industry standards.
Key Customers
- Wholesalers and distributors of pharmaceutical products.
- Retail pharmacy chains and mail-order pharmacies.
- Group purchasing organizations (GPOs).
- Independent pharmacies, hospitals, and nursing homes.
Financials
Chart & Info
Health-Chem Corporation (HCLC) stock price: Price data unavailable
Latest News
No recent news available for HCLC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HCLC.
Price Targets
Wall Street price target analysis for HCLC.
MoonshotScore
What does this score mean?
The MoonshotScore rates HCLC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Ronald J. Burghauser
CEO
Ronald J. Burghauser serves as the CEO of Health-Chem Corporation, leading the company's strategic direction and overseeing its operations. His background includes extensive experience in the pharmaceutical industry, with a focus on sales, marketing, and business development. He has held various leadership positions in both established pharmaceutical companies and emerging biotechnology firms. He is responsible for managing the company's 55 employees and driving its growth initiatives.
Track Record: Under Ronald J. Burghauser's leadership, Health-Chem Corporation has focused on maintaining its market position in the transdermal nitroglycerin patch market and expanding its contract R&D services. Key achievements include securing several new R&D contracts and streamlining manufacturing processes to improve efficiency. He has also focused on building strategic relationships with key distributors and wholesalers.
HCLC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to the OTC Other tier status.
- Thin trading volume and wide bid-ask spreads.
- Higher potential for fraud and manipulation compared to listed exchanges.
- Lack of regulatory oversight and investor protection.
- Going Concern risk.
- Verify the company's management team and their experience.
- Review any available financial statements and assess their accuracy.
- Research the company's business model and competitive landscape.
- Assess the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any history of regulatory issues or lawsuits.
- Longevity in the market (founded in 1970).
- Focus on a specific niche within the pharmaceutical industry.
- Contract R&D services indicating technical expertise.
- Established distribution network in the United States.
HCLC Healthcare Stock FAQ
What does Health-Chem Corporation do?
Health-Chem Corporation, through its subsidiary Transderm Laboratories Corporation, specializes in the research, development, manufacture, and marketing of transdermal drug delivery systems. Their primary product is the transdermal nitroglycerin patch, used for relieving vascular and cardiovascular symptoms related to angina. Additionally, they engage in contract research and development for other companies, leveraging their expertise in transdermal technology. The company distributes its products through various channels, including wholesalers, retail pharmacies, and healthcare organizations throughout the United States.
What do analysts say about HCLC stock?
As of March 16, 2026, there is no readily available analyst coverage or consensus on Health-Chem Corporation (HCLC) stock, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the company's financial performance, market position, and growth prospects before making any investment decisions. Key valuation metrics, such as P/E ratio and profit margin, should be carefully evaluated in the context of the company's industry and competitive landscape. The absence of analyst coverage underscores the need for independent research and risk assessment.
What are the main risks for HCLC?
Health-Chem Corporation faces several key risks, including its high reliance on a single product (nitroglycerin patches), which makes it vulnerable to competition and regulatory changes. The company's negative profit margin indicates financial instability and the need for improved cost management. As an OTC-listed company, HCLC is subject to less stringent regulatory oversight, increasing the risk of fraud and manipulation. Additionally, technological advancements in alternative drug delivery methods could erode the demand for transdermal patches. Investors should carefully consider these risks before investing in HCLC.
What are the key factors to evaluate for HCLC?
Health-Chem Corporation (HCLC) currently holds an AI score of 38/100, indicating low score. Key strength: Specialized expertise in transdermal drug delivery.. Primary risk to monitor: Ongoing: High reliance on a single product (nitroglycerin patches).. This is not financial advice.
How frequently does HCLC data refresh on this page?
HCLC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HCLC's recent stock price performance?
Recent price movement in Health-Chem Corporation (HCLC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in transdermal drug delivery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HCLC overvalued or undervalued right now?
Determining whether Health-Chem Corporation (HCLC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HCLC?
Before investing in Health-Chem Corporation (HCLC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market carries higher risks compared to listed exchanges.